Latest filing published 23 Dec 2014 for SALIX PHARMACEUTICALS LTD, €634k.
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Carolyn J. Logan: trading record in brief
Carolyn J. Logan is a declared insider of Salix Pharmaceuticals Ltd, with filings sourced from SEC (Form 4). The record holds 72 filings, for trades running from 2 March 2006 to 22 December 2014.
Both buying and selling appear: 2 purchases worth €128k, against 13 sales worth €11.4M. Netting one side against the other leaves €11.3M of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 20 share grants and 14 option exercises. 2014 to date brings no purchases and 3 sales.
The record was last updated on 23 December 2014 with an option exercise (€634k) in Salix Pharmaceuticals Ltd. The last insider purchase was made public on 19 November 2007, 6,929 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Carolyn J. Logan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 44,000 shares@ US$17.63Common StockSEC:0001209191-14-077766:0
- 46,684 shares@ US$158.30Common StockSEC:0001209191-14-054528:0
- 8,253 shares@ US$123.35Common StockSEC:0001209191-14-045982:0
- 33,750 shares@ US$18.87Common StockSEC:0001209191-14-044401:0
- 65,625 shares@ US$18.87Common StockSEC:0001209191-14-044401:1
- 19,200 shares@ US$123.87Common StockSEC:0001209191-14-044401:2
- 32,857 shares@ US$123.13Common StockSEC:0001209191-14-044401:3
- 1,000 shares@ US$122.38Common StockSEC:0001209191-14-044401:4
- 73,684 shares@ US$100.66Common StockSEC:0001209191-14-028487:0
- 400,000 shares0Common StockSEC:0001209191-14-018355:0
- 400,000 shares0Common StockSEC:0001209191-14-018355:1
- 400,000 shares0Common StockSEC:0001209191-14-011870:0
- 400,000 shares0Common StockSEC:0001209191-14-011870:1
- 34,055 shares@ US$89.94Common StockSEC:0001209191-14-001853:0
- 20,113 shares@ US$66.15Common StockSEC:0001209191-13-035577:0
- 400,000 shares0Common StockSEC:0001209191-13-033376:0
- 247,761.2 shares0Common StockSEC:0001209191-13-033376:1
- 94,199 shares@ US$48.70Common StockSEC:0001209191-13-022197:0
- 22,268 shares@ US$40.47Common StockSEC:0001209191-13-002117:0
- 33,750 shares@ US$7.60Common StockSEC:0001209191-12-059070:0
- 25,000 shares@ US$42.27Common StockSEC:0001209191-12-059070:1
- 17,357 shares@ US$54.44Common StockSEC:0001209191-12-037339:0
- 228,467 shares@ US$4.07Common StockSEC:0001209191-12-036236:0
- 119,300 shares@ US$52.07Common StockSEC:0001209191-12-036236:1
- 36,534 shares@ US$4.07Common StockSEC:0001209191-12-034284:0
25 of 70 declarations